Delivered first clinical validation of the Recursion full stack AI Operating System in FAP, demonstrating translation from AI-driven biological insight to meaningful patient outcomes; multiple ...
Recursion Pharmaceuticals (NASDAQ:RXRX) presented its fourth quarter and full-year 2025 results on February 25, 2026, showcasing the first clinical validation of its AI-driven drug discovery platform ...
SALT LAKE CITY, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and ...
This database originally covered cases from 1982 to 2012 and has since been updated and expanded numerous times. For analysis and context on this data—including how we built the database, and a change ...
With eight years of experience as a financial journalist and editor and a degree in economics, Elizabeth Aldrich has worked on thousands of articles within the realm of banking, economics, credit ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results